Novo Nordisk has made its smart insulin pens available in the UK, giving people treated within the NHS for diabetes access to devices that can monitor and record dosing information for the first time.

The global insulin delivery pens market size is predicted to increase from USD 25,578 million in 2025 and is anticipated to reach around USD 58,086 million by 2034, expanding at a CAGR of 8.2% from ...

Novo Nordisk’s insulin brand Mixtard will continue to be available in vials, the Danish healthcare company clarified, even as it phases out its penfill. The penfill is being phased out as part of ...

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Novo Nordisk is collaborating with multiple telehealth organizations in an effort to increase patient access to authentic Wegovy.

Novo Nordisk clarifies Human Mixtard penfill to be replaced with injectables: Our Bureau, Bengaluru Wednesday, April 23, 2025, 13:30 Hrs [IST] Denmark-based global pharma major, N ...

Ellison says the settlement requires Novo Nordisk to provide insulin products—including ... per monthly prescription (3 vials or 2 packs of pens) for customers paying with cash.

A partial phase out of a top insulin product by Danish drug maker Novo Nordisk may open a bounty for Eris Pharma and its ...

Also read: Novo Nordisk to continue India's largest ... This may limit the access further as insulin delivery from pen devices is preferred by a huge majority of diabetics over vials injected ...